Aurobindo Pharma has completed acquisition of balance 49% of equity shares of GLS Pharma. Earlier, the company had entered into a binding agreement on September 18, 2024, with GLS Pharma, a subsidiary of the Company and its promoters for acquisition of balance 5,90,361 equity shares of Rs 10 each (49% of GLS Pharma) for a purchase consideration of Rs 22.5 crore.
The aforementioned acquisition has been completed on October 25, 2024 and GLS has become a wholly owned subsidiary of the company.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
